Maureen Megan O'Brien MD (She/Her)
Pediatric Hematologic Oncology
Professor, University of Colorado School of Medicine, Children's Hospital Colorado
Join to View Full Profile
13123 East 16th AvenueBox B115Aurora, CO 80045
Phone+1 720-777-6863
Fax+1 720-777-7227
Dr. O'Brien is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford University School of MedicineMS, Epidemiology, 2007 - 2008
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 2004 - 2007
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2000 - 2003
Harvard Medical SchoolClass of 2000- Harvard UniversityAB, Biochemical Sciences, Summa Cum Laude, 1992 - 1996
Certifications & Licensure
CA State Medical License 2004 - Present
CO State Medical License 2023 - 2027
SD State Medical License Active through 2027
MT State Medical License Active through 2026
NM State Medical License 2025 - 2025- SD State Medical License Active through 2025
WY State Medical License 2024 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology- Join now to see all
Clinical Trials
- A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2011 Apr 14
- Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma Start of enrollment: 2012 Aug 01
- A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsHigh-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531.Johann Hitzler, Todd A. Alonzo, Robert B. Gerbing, Amy Beckman, Betsy A. Hirsch
Blood. 2021-07-28 - 4 citationsTreatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effectiveJeremy D. Rubinstein, Rachana Shah, Erin H. Breese, Karen Burns, Jennifer Mangino
Pediatric Blood & Cancer. 2021-05-21 - 2 citationsResults of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemiaMaureen M. O'Brien, Todd A. Alonzo, Todd Cooper, John E. Levine, Patrick A. Brown
Pediatric Blood & Cancer. 2021-03-10
Abstracts/Posters
- Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...Maureen M O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)Maureen M O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute LeukemiaMaureen M O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731December 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
